References
- Baker DL, Peng K, Cheu M, Fischer SK. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. Curr Med Res Opin 2014;30:913-22
- Strohner P. Patent: EP 06828568.3. Immunoassay for the simultaneous immunochemical determination of an analyte (antigen) and a treatment antibody targeting the analyte in samples (recovery immunoassay). AT454629 (T) -2010-01-15 European Patent Office
- Strohner P, Staatz A, Sarrach D, et al. The recovery ELISA – a newly developed immunoassay for measurement of therapeutic antibodies and the target antigen during antibody therapy. Clin Chem Lab Med 2012;50:1263-9
- Strohner P, Korn S, Buhl R, Becher G. The recovery-ELISA – a novel assay technique to monitor therapy with humanized antibodies: the example of omalizumab. J Immunoassay Immunochemistry 2013;34:83-93
- BioTeZ Berlin-Buch GmbH: RIO user manual – instructions for enzyme immunoassay for the quantitative in-vitro determination of free IgE and available therapeutic antibody omalizumab in human serum samples. Available at: http://www.biotez.de/index.php/de/unternehmen/downloads.html [Version 4, Last accessed 6 May 2014]
- Document WC 500 057 298 from EMA – Annex I – Summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000606/WC500057298.pdf [Last accessed 4 April 2014]